Magical 67 to 23

[Anonymous]

Now it possible that the whole portfolio might be shyer than 23. All top cancer portfolio is dead on arrival -- that is, patient and the portfolio. MSK is sightly better but with nöż running the show, expect the "Masscare of the Building48". Alarm pheromones are being gently introduced in familiar settings (one-2-One) which will elevate the fear pro-pheromones of the said species laying a ground for mass hysteria in ensuing la primavera.

 

[Anonymous]

Building 48 will be turned into a museum/mausoleum of FIPNet folly. NSD will not replacement their VP in order to save $$, as the whole research area is punted. The onco. strategy of kinase inhibtors & imclone-ibodies will be another staggering failures. Look for pasta primavera to be served in a prelude to the massive cuts coming in that timeframe.

 

[Anonymous]

Building 48 will be turned into a museum/mausoleum of FIPNet folly. NSD will not replacement their VP in order to save $$, as the whole research area is punted. The onco. strategy of kinase inhibtors & imclone-ibodies will be another staggering failures. Look for pasta primavera to be served in a prelude to the massive cuts coming in that timeframe.

Well said!!!

Mr. Liecheater, their is cancer growing in cancer - 98% of the portfolio is hyped up joke. Just ask Roche and Novartis. Mark my word - Lilly will not have a single cancer drug past Phase 3 in next 15 years at the best. This is a sort of the undercurrent that spreaded the real estate bubble...only enlightened one understands.